News & Perspective

Dec 26, 2012

Dec 26, 2012

Experts differ on HHS select-agent proposal for H5N1

(CIDRAP News) – Some professional groups and scientists think it's a good idea to classify highly pathogenic avian (HPAI) H5N1 influenza viruses as "select agents" requiring special research precautions, while others say the step is unnecessary and would impede research, according to comments they have filed with the US Department of Health and Human Services (HHS).

Dec 18, 2012

Dec 18, 2012

Experts at NIH meeting say H5N1 research moratorium may end soon

(CIDRAP News) – As a meeting to discuss issues related to federally funded H5N1 avian influenza research wrapped up today, experts anticipated that a voluntary moratorium on work with lab-modified strains that have increased transmissibility might end soon and said they sensed agreement about lab biosecurity levels.

Dec 17, 2012

Dec 17, 2012

H5N1 researchers question proposed HHS funding framework

(CIDRAP News) – Federal health officials are in the midst of crafting a framework for funding H5N1 avian influenza gain-of-function studies, and today at a workshop they heard varied feedback from researchers, biosecurity experts, and others.

Dec 13, 2012

Dec 13, 2012

With new rules, few public health labs to handle riskiest agents

(CIDRAP News) – With tougher security requirements set to take effect next April, few state public health laboratories plan to maintain stocks of certain pathogens considered most tempting to bioterrorists, according to the Association of Public Health Laboratories (APHL) and officials with state labs.

Dec 11, 2012

Dec 11, 2012

HHS offers some forecasts on medical countermeasures

(CIDRAP News) – A new report from the US Department of Health and Human Services (HHS) offers a few predictions on when certain new countermeasures against biological threats will become available, including a forecast for two novel influenza drugs and possibly a next-generation anthrax vaccine within the next 5 years.

Nov 21, 2012

Nov 21, 2012

FDA clears first cell-based flu vaccine

(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the nation's first cell-based flu vaccine, a product from Novartis that uses technology that could help vaccinate more Americans in a pandemic but still has many of the same limitations of older egg-based flu vaccines.

Nov 19, 2012

Nov 15, 2012

Nov 15, 2012

FDA panel endorses H5N1 vaccine with adjuvant

(CIDRAP News) – A government advisory committee yesterday endorsed the safety and immunogenicity of an adjuvant-containing H5N1 influenza vaccine proposed for inclusion in the US pandemic emergency stockpile, signaling that it could become the first adjuvanted flu vaccine to win approval in the United States.

Pages

Sort Results

 

Narrow results

by Topic

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»